blood cancer

(iStock image)
November 25, 2024

Potential treatment eyed for abnormal blood cell disorder

Research could lead to improved diagnosis and the first effective treatment for the disorder, called “clonal hematopoiesis of indeterminant potential,” or CHIP. 

By Bill Snyder
(iStock)
November 4, 2024

Tae Kon Kim receives V Foundation grant for MDS drug research 

Kim and colleagues will study whether this protein hinders the ability of the immune system to fight MDS and whether it can be blocked to treat MDS.

By Tom Wilemon
Graduate student Taralynn Mack, left, pipettes a sample while Alexander Bick, MD, graduate student Hannah Poisner, and Celestine Wanjalla, MD, PhD, look on.
June 4, 2024

Research raises hope for treating potentially lethal blood condition

Roughly 1 in 10 people over age 70 will develop CHIP, an explosive, clonal growth of abnormal blood cells that increases risk of blood cancers and death from cardiovascular, lung and liver disease.

By Bill Snyder
(iStock image)
April 24, 2024

VUMC hosts symposium on stem cell transplants and cellular therapies

The Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium offers clinicians detailed information on the latest developments for hematological diseases, ranging from immunotherapies for blood cancers to new, curative therapies for sickle cell disease.

By Tom Wilemon
March 28, 2024

Study identifies molecule as potential target for treating AML

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 

By Tom Wilemon
January 4, 2024

Potential AML therapy induces leukemic stem cell death

Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.

By Tom Wilemon
December 5, 2023

Eden Biltibo is Multiple Myeloma Research Foundation scholar recipient

Vanderbilt’s Eden Biltibo, MD, MS, is one of the first recipients of the Multiple Myeloma Research Foundation’s Scholars Program, an initiative launched in 2022.
By Tom Wilemon
September 27, 2023

Being treated for childhood cancer set Jason Schwartz on the path to his life’s work: treating childhood cancer

Cancer at the age of 13 forced him to give up his dream of professional football. While undergoing treatment, he found a new dream.
By Jessica Pasley
July 20, 2023

Stem cell recipient meets donor who saved her life 10 years ago

Each passing day is precious for Deneen Eastridge, but a decade is a priceless gift. The Dallas resident came to Nashville recently to meet Trina Hughes, the stem cell donor who gave her the gift of life 10 years ago.
By Tom Wilemon
April 12, 2023

Research identifies new target that may prevent blood cancer

An international coalition of biomedical researchers co-led by Vanderbilt's Alexander Bick, MD, PhD, has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients’ risk of blood cancer.
By Bill Snyder
March 30, 2023

VUMC researcher selected for Global Scholars Program

Vanderbilt researcher P. Brent Ferrell, MD, is leading one of five projects selected by the 2022 Novartis Institutes for BioMedical Research Global Scholars Program.
By Leigh MacMillan
February 2, 2023

Researchers clarify role of blood cell mutations in disease

Vanderbilt researchers have developed a new method to analyze mutations in blood stem cells that can trigger explosive, clonal expansions of abnormal cells.
By Bill Snyder
January 12, 2023

Chan Zuckerberg Initiative grant supports single-cell study of rare inherited disease

A multidisciplinary team led by Vanderbilt University Medical Center investigator Alexander Bick, MD, PhD, has been awarded a $2 million, four-year grant to study inflammation at the single-cell level in the rare disease RUNX1-FPD.
By Leigh MacMillan
1 2 3 4